CAJ | 학술논문

目的探讨化疗前后晚期非小细胞肺癌(NSCLC)患者血清WASP家族verprolin同源蛋白1(WAVE1)和血管内皮生长因子C(VEGF-C)表达水平的变化及其临床意义.方法应用酶联免疫吸附法(ELISA)检测43例晚期NSCLC患者化疗前后血清WAVE1和VEGF-C的表达水平,选取43名健康人作为对照组.结果肺癌组化疗前血清WAVE1及VEGF-C水平分别为(0.573±0.082)ng/ml、(947.3±125.4) pg/ml,健康对照组分别为(0.256±0.064)ng/ml、(425.5±110.1) pg/ml,肺癌组化疗前血清WAVE1及VEGF-C水平均高于健康对照组,差异均有统计学意义(均P＜ 0.05).肺癌组患者血清WAVE1和VEGF-C表达与淋巴结转移及远处转移有关(P＜0.05),与患者性别、年龄、肿瘤大小、组织类型、分化程度、TNM临床分期无关(P＞0.05).肺癌组化疗后有效组血清WAVE1及VEGF-C水平分别为(0.290±0.037)ng/ml、(596.1±127.5) pg/ml,均低于化疗前的(0.589±0.085)ng/ml、(951.6± 120.7)pg/ml,差异有统计学意义(均P＜0.05).而无效组化疗前后血清WAVE1及VEGF-C水平比较,差异均无统计学意义(均P＞ 0.05).化疗前后肺癌组血清WAVE1及VEGF-C水平呈正相关(r=0.331、r=0.540,均P＜0.05).结论化疗前后血清WAVE1及VEGF-C浓度变化可能成为预测晚期NSCLC患者化疗效果的有用指标.
목적 탐토화료전후만기비소세포폐암(NSCLC)환자혈청WASP가족verprolin동원단백1(WAVE1)화혈관내피생장인자C(VEGF-C)표체수평적변화급기림상의의.방법 응용매련면역흡부법(ELISA)검측43례만기NSCLC환자화료전후혈청WAVE1화VEGF-C적표체수평,선취43명건강인작위대조조.결과 폐암조화료전혈청WAVE1급VEGF-C수평분별위(0.573±0.082)ng/ml、(947.3±125.4) pg/ml,건강대조조분별위(0.256±0.064)ng/ml、(425.5±110.1) pg/ml,폐암조화료전혈청WAVE1급VEGF-C수평균고우건강대조조,차이균유통계학의의(균P＜ 0.05).폐암조환자혈청WAVE1화VEGF-C표체여림파결전이급원처전이유관(P＜0.05),여환자성별、년령、종류대소、조직류형、분화정도、TNM림상분기무관(P＞0.05).폐암조화료후유효조혈청WAVE1급VEGF-C수평분별위(0.290±0.037)ng/ml、(596.1±127.5) pg/ml,균저우화료전적(0.589±0.085)ng/ml、(951.6± 120.7)pg/ml,차이유통계학의의(균P＜0.05).이무효조화료전후혈청WAVE1급VEGF-C수평비교,차이균무통계학의의(균P＞ 0.05).화료전후폐암조혈청WAVE1급VEGF-C수평정정상관(r=0.331、r=0.540,균P＜0.05).결론 화료전후혈청WAVE1급VEGF-C농도변화가능성위예측만기NSCLC환자화료효과적유용지표.
Objective To evaluate the level changes of serum WASP-family verprolin homologous protein-1 (WAVE1) and vascular endothelial growth factor-C (VEGF-C) and their clinical significance in patients with advanced non-small lung cancer (NSCLC) before and after chemotherapy.Methods Serum WAVE1 and VEGF-C were measured in 43 patients with advanced NSCLC by ELISA,and the results were compared with 43 healthy volunteers.Results The levels of serum WAVE1 and VEGF-C before chemotherapy in patients group were (0.573±0.082) ng/ml and (947.3±125.4) pg/ml respectively,while in healthy volunteers group,they were (0.256±0.064) ng/ml and (425.5±110.1) pg/ml respectively,which suggested that before chemotherapy the levels of serum WAVE1 and VEGF-C in NSCLC group were significantly higher than those of in the control (P ＜ 0.05).The serum levels of WAVE1 and VEGF-C in advanced NSCLC patients were closely related to lymph node metastasis status and distant metastasis status (P ＜ 0.05),but not to the gender,age,tumor length,histology type,differentiation grade and C-TNM stage (P ＞ 0.05).The serum WAVE1 and VEGF-C levels of the effective treatment group was (0.290±0.037) ng/ml and (596.1±127.5) pg/ml after chemotherapy respectively,which decreased obviously compared with the group before chemotherapy which levels were (0.517±0.051) ng/ml and (964.6±100.3) pg/ml (both P ＜ 0.05).But the serum WAVE1 and VEGF-C levels of the ineffective treatment group were (0.547±0.065) ng/ml and (957.0±111.2) pg/ml after treatment,which had no difference compared with the group before chemotherapy which levels were (0.517±0.051) ng/ml and (964.6±100.3) pg/ml (both P ＞ 0.05).Furthermore,statistically significant relationship was found between the serum WAVE1 and the VEGF-C levels (r =0.331,r =0.540,both P ＜ 0.05).Conclusion Serum WAVE1 and VEGF-C may be used as indicators for prediction of the efficacy of chemotherapy in patients with advanced NSCLC.